SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVII - AVI BioPharma (Cancer Vaccine) -- Ignore unavailable to you. Want to Upgrade?


To: bob zagorin who wrote (271)5/7/2007 9:15:02 AM
From: DELT1970  Respond to of 284
 
AVI BioPharma Receives DoD Contracts for Bioterrorism Response Therapies
Monday May 7, 9:00 am ET
Funding Will Advance Antisense Programs Targeting Ebola and Marburg Viruses, Anthrax, and Ricin Exposure

PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq: AVII - News), today announced the receipt of three signed contracts valued at $7.1 million from the Department of Defense for the development of therapeutic drugs against potential bioterrorism agents, using AVI's NEUGENE® technology. The contracts, including $2.66 million to develop antisense agents to treat Ebola virus infections, $2.66 million to treat Marburg virus infections, and $1.78 million to develop countermeasures for exposure to Bacillus anthracis (anthrax) and ricin toxin, were part of a previously announced budget allocation.
biz.yahoo.com